Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-PD
ACTRN12626000740392Phase 2Recruiting
- Sponsor
- Curtin University
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Lorelco with Placebo (2 arms). Primary endpoint: Change in MDS-UPDRS Part III motor score. Started Sep 2026; status: recruiting.
02
Drugs
probucol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12626000740392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000740392.